BANK VONTOBEL/PUT/BIOGEN IDEC/240/0.01/20.09.24 | Market Closed - Deutsche Boerse AG 19:02:02 28/06/2024 BST | ||
| 0.166 EUR | -4.60% |
|
| Current month | -19.42% | ||
| 1 month | -33.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.166 | -4.60% |
| 27/06/24 | 0.174 | -12.56% |
| 26/06/24 | 0.199 | +4.19% |
| 25/06/24 | 0.191 | +10.40% |
| 24/06/24 | 0.173 | -12.18% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 07:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MKE |
| ISIN | DE000VM3MKE8 |
| Date issued | 06/10/2023 |
| Strike | 240 $ |
| Maturity | 20/09/2024 (82 Days) |
| Parity | 100 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.47 € |
|---|---|
| Lowest since issue | 0.144 € |
| Spread | 0.01 € |
| Spread % | 6.02% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8
USD
Average target price
283.2
USD
Spread / Average Target
+22.14%
- Stock Market
- Warrants
- Warrant
